FrancophonIA/ELRC3.0 huggingface dataset:
English: In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p=0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event.
Maltese: Fl-analiżi tal-intenzjoni tal-kura, ġew osservati 939 każ fil-grupp ta' clopidogrel u 1,020 każ ma' ASA (tnaqqis tar-riskju relattiv, relative risk reduction (RRR)) 8.7%, [95% CI: 0.2 sa 16.4]; p = 0.
English: After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed.
Maltese: Wara doża orali waħda u ripetuta ta' 75 mg kuljum, clopidogrel kien assorbit malajr b'rata mgħaġġla.
English: - a recent surgery (including dental).
Maltese: operazzjoni riċenti (anki tas-snien);
English: TOPIC (Timing Of Platelet Inhibition after acute Coronary syndrome) This randomized, open-label trial included ACS patients requiring PCI.
Maltese: TOPIC (L-Aħjar Żmien għall-Inibizzjoni tal-Plejtlits wara sindromu Koronarju akut - Timing Of Platelet Inhibition after acute Coronary syndrome)
English: • You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects').
Maltese: • Għandek tgħarraf lit-tabib tiegħek minnufih ukoll jekk tiżviluppa kundizzjoni medika (li hi magħrufa wkoll bħala Purpura Tromboċitopenika Trombotika jew TTP) li tinkludi deni u tbenġila taħt il-ġilda li jista' jidher bħala dbabar ħomor irqaq, bi jew mingħajr għeja kbira mhux spjegabbli, konfużjoni,
English: The most common side effect reported with Clopidogrel Teva is bleeding.
Maltese: L-aktar effett kollaterali komuni rapportat bi Clopidrogrel Teva hu l-emorraġija.
English: Name and address of the manufacturers responsible for batch release
Maltese: Avvenimenti ta' fsada definiti bħala kollha BARC
English: As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors, or selective serotonin reuptake inhibitors (SSRIs), or other medicinal products associated with bleeding risk such as pentoxifylline (see section 4.5).
Maltese: glycoprotein IIb/IIIa jew mediċini kontra l-infjammazzjoni li m'humiex sterojdi (NSAIDS) li jinkludu linibituri ta' Cox-2, jew inibituri selettivi tal-ġbir mill-ġdid ta' serotonin (SSRIs), jew prodotti mediċinali marbuta ma' riskju ta' fsada bħal pentoxifylline (ara sezzjoni 4.5).
English: Pharmacogenetics: In patients who are poor CYP2C19 metabolisers, clopidogrel at recommended doses forms less of the active metabolite of clopidogrel and has a smaller effect on platelet function.
Maltese: F'pazjenti li għandhom metabolizzaturi dgħajfin ta' CYP2C19, clopidogrel f'dożi rakkomandati jifformaw inqas mis-sustanza attiva ta' clopidogrel u għandhom inqas effett fuq il-funzjoni tal-plejtlits.
English: Do not use this medicine after the expiry date which is stated on the outer carton, bottle or blister, after EXP.
Maltese: Tużax din il-mediċina wara d-data ta' meta tiskadi li tidher fuq il-kartuna u fuq il-folja, wara EXP.
English: The CURE study included 12,562 patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischaemia.
Maltese: Sindromu koronarju akut L-istudju CURE kien jinkludi 12,562 pazjent bis-sindromu koronarju akut tas-segment mhux-ST elevat
English: Taste disturbances, ageusia
Maltese: stitikezza, gass
English: • chronic myeloid leukaemia (CML);
Maltese: • lewkimja malejojde kronika (CML);
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom24 October 2014 EMA/641476/2014
Maltese: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
English: • acute lymphoblastic leukaemia (ALL) in patients who are ‘Philadelphia-chromosome positive' (Ph+).
Maltese: • lewkimja limfoblastika akuta (ALL) f'pazjenti li huma ‘pożittivi għall-kromożomju Phildelphia' (Ph+).
English: • The benefit-risk balance of Iclusig remains positive in all authorised indications, and the starting dose remains 45 mg per day.
Maltese: • Il-bilanċ benefiċċju-riskju ta' Iclusig jibqa' wieħed pożittiv fl-indikazzjonijiet awtorizzati kollha, u ddoża inizjali tibqa 45 mg kuljum.
English: • Safety and efficacy data concerning dose reduction following major cytogenetic response in chronic phase CML patients have been included in the SmPC, to provide information to the prescriber and to facilitate an individual assessment of the benefit-risk balance of Iclusig with regards to dose reduction.
Maltese: • Data dwar is-sigurtà u l-effikaċja li tikkonċerna tnaqqis fid-doża wara rispons ċitoġenetiku maġġuri f'pazjenti b'CML fil-fażi kronika ġiet inkluża fl-SmPC, biex tipprovdi informazzjoni lil min jippreskrivi u biex tiffaċilita evalwazzjoni individwali tal-bilanċ benefiċċju-riskju ta' Iclusig fir-rigward ta' tnaqqis tad-doża.
English: It is also used in patients who have a genetic mutation called ‘T315I mutation' which makes them resistant to treatment with imatinib, dasatinib or nilotinib.
Maltese: Jintuża wkoll f'pazjenti li għandhom mutazzjoni ġenetika msejħa ‘mutazzjoni T315I' li tagħmilhom reżistenti għal kura b'imatinib, dasatinib jew nilotinib.
English: The active substance in Iclusig, ponatinib, belongs to a group of medicines called ‘tyrosine-kinase inhibitors'.
Maltese: Is-sustanza attiva f'Iclusig, il-ponatinib, tagħmel parti minn grupp ta' mediċini msejħin ‘inibituri tirożina-kinażi'.
English: Iclusig was authorised as an orphan medicine (a medicine to treat rare diseases) in the EU in July
Maltese: Iclusig ġie awtorizzat bħala mediċina orfni (mediċna għall-kura ta' mard rari) fl-UE f'Lulju 2013.
English: Any assessment relating to dose reduction should take into account a number of factors, including the patient's cardiovascular risk, side effects of therapy, and time to cytogenetic response.
Maltese: Kwalunkwe evalwazzjoni relatata ma' tnaqqis tad-doża għandha tqis numru ta' fatturi, inklużi r-riskju kardjovaskulari tal-pazjent, l-effetti sekondarji tat-terapija, u ż-żmien għal rispons ċitoġenetiku.
English: Iclusig is authorised for use in patients with chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL) who cannot take or tolerate several other medicines of the same class (known as ‘tyrosine-kinase inhibitors').
Maltese: Iclusig huwa awtorizzat għal użu f'pazjenti b'lewkimja majelojde kronika (CML) u lewkimja limfoblastika akuta (ALL) li ma jistgħux jieħdu jew jittolleraw diversi mediċini oħrajn tal-istess grupp (magħrufin bħala ‘inibituri tirożina-kinażi').
English: The review of Iclusig was initiated on 27 November 2013 at the request of the European Commission, under Article 20 of Regulation (EC) No 726/2004.
Maltese: Ir-rieżami ta' Iclusig inbidel fis-27 ta' Novembru 2013 fuq talba tal-Kummissjoni Ewropea, skont lArtikolu 20 tar-Regolament (KE) Nru 726/2004
English: The cardiovascular status of the patient should be assessed before starting therapy with Iclusig, and regularly monitored during treatment.
Maltese: Il-qagħda kardjovaskulari tal-pazjent għandha tiġi evalwata qabel jibda terapija b'Iclusig, u għandha tiġi mmonitorjata regolarment matul il-kura.
English: Iclusig is a medicine used to treat adults with the following types of leukaemia (cancer of the white blood cells):
Maltese: Iclusig huwa mediċina li tintuża fil-kura ta' adulti bit-tipi ta' lewkimja (kanċer taċ-ċelloli tad-demm bojod) li ġejjin:
English: • Educational material will be provided to healthcare professionals, highlighting important risks for which monitoring and/or dose adjustments are recommended.
Maltese: • Ser jiġi pprovdut materjal edukattiv lill-professjonisti tal-kura tas-saħħa, li jenfasizza riskji importanti li għalihom huwa rrakkomandat monitoraġġ u/jew aġġustament tad-doża.
English: The company that markets Iclusig will provide healthcare professionals with educational material highlighting important risks for which monitoring and/or dose adjustments are recommended and including available data on the relationship between dose of Iclusig and risk of blood vessel blockage.
Maltese: Il-kumpanija li tqiegħed Iclusig fis-suq ser tipprovdi lill-professjonisti tal-kura tas-saħħa b'materjal edukattiv li jenfasizza riskji importanti li għalihom huwa rrakkomandat monitoraġġ u/jew aġġustament tad-doża u ser ikun hemm inkluż data disponibbli dwar ir-relazzjoni bejn id-doża ta' Iclusig u r-riskju ta' mblokkar tal-arterji u l-vini.
English: By blocking Bcr-Abl, Iclusig helps to control the growth and spread of leukaemia cells.
Maltese: Billi jimblokka Bcr-Abl, Iclusig jgħin biex jikkontrolla t-tkabbir u l-firxa taċ-ċelloli tal-lewkimja.
English: The review followed a previous assessment of clinical trial data which indicated that cases of blood clots and blockages in the arteries or veins were occurring at a higher rate than was observed at the time of the medicine's initial authorisation.
Maltese: Ir-rieżami segwa evalwazzjoni preċedenti ta' data tal-provi kliniċi li indikat li bdew iseħħu każijiet ta' emboli u mblokki fl-arterji jew fil-vini b'rata ogħla minn dik osservata fiż-żmien tal-awtorizzazzjoni inizjali tal-mediċina.
English: Ponatinib works by blocking a tyrosine kinase (an enzyme) called Bcr-Abl, which is found in some receptors on the surface of the cancer cells where it is involved in stimulating the cells to divide uncontrollably.
Maltese: Il-ponatinib jaħdem billi jimblokka t-tirożina kinażi (enżima) imsejħa Bcr-Abl, li tinsab f'xi riċetturi fuq il-wiċċ taċ-ċelloli tal-kanċer fejn tkun involuta fl-istimulazzjoni taċ-ċelloli biex jiddividu b'mod inkontrollabli.
English: The European Medicines Agency (EMA) has concluded its review of the benefits and risks of Iclusig (ponatinib), a medicine used for the treatment of leukaemia (cancer of the white blood cells), and has recommended strengthened warnings in the product information aimed at minimising the risk of blood clots and blockages in the arteries.
Maltese: Fit-23 ta' Ottubru 2014, l-Aġenzija Ewropea għall-Mediċini (EMA) temmet ir-rieżami tagħha talbenefiċċji u r-riskji ta' Iclusig (ponatinib), mediċina li tintuża għall-kura ta' lewkimja (kanċer taċ-ċelloli tad-demm bojod), u rrakkomandat twissijiet imsaħħa fl-informazzjoni tal-prodott immirati lejn ittnaqqis tar-riskju ta' emboli u mblokki fl-arterji.
English: The available evidence shows that the risk of blood vessel blockage with Iclusig is likely to be doserelated, however the data are insufficient to formally recommend the use of lower doses of Iclusig, and there is a risk that lower doses might not be as effective in all patients and in long-term treatment.
Maltese: L-evidenza disponibbli turi li r-riskju ta' mblokkar ta' vini b'Iclusig x'aktarx huwa relatat mad-doża, madankollu id-data mhijiex biżżejjed biex jiġi rrakkomandat b'mod formali l-użu ta' dożi iktar baxxi ta' Iclusig, u hemm riskju li dożi iktar baxxi jistgħu ma jkunux daqshekk effettivi fil-pazjenti kollha f'kura fit-tul.
English: The PRAC recommendations were then sent to the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which adopted the Agency's final opinion.
Maltese: Ir-rakkommandazzjonijiet tal-PRAC imbagħad intbagħtu lillKumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP), responsabbli mill-mistoqsijiet li jikkonċernaw mediċini għall-użu mill-bniedem, li adotta l-opinjoni finali tal-Aġenzija.
English: Iclusig is used in patients who cannot tolerate or do not respond to dasatinib or nilotinib (other medicines for the treatment of leukaemia) and for whom subsequent treatment with imatinib is not considered appropriate.
Maltese: Iclusig jintuża f'pazjenti li ma jistgħux jittolleraw jew ma jagħtux rispons għal dasatinib jew nilotinib (mediċini oħrajn għall-kura tal-lewkimja) u għal min, kura sussegwenti b'imatinib mhijiex ikkunsidrata xierqa.
English: The product information will be updated with strengthened warnings about the risks with Iclusig, and to also provide healthcare professionals with the latest evidence in case they wish to consider reducing the dose of Iclusig in patients with ‘chronic phase' CML who are responding well to treatment, and who might be at particular risk of blood vessel blockage.
Maltese: Għalhekk, id-doża inizjali ta' Iclusig irrakkomandata għandha tibqa' 45 mg darba kuljum. Linformazzjoni tal-prodott ġiet aġġornata bi twissijiet imsaħħa dwar ir-riskju b'Iclusig, u biex tipprovdi wkoll lill-professjonisti tal-kura tas-saħħa bl-evidenza l-iktar reċenti fil-każ li jkunu jixtiequ jikkunsidraw tnaqqis tad-doża ta' Iclusig f'pazjenti b'CML fil-‘fażi kronika' li jkunu qed jagħtu rispons tajjeb għall-kura, u li jistgħu jkunu f'riskju partikolari ta' mblokkar tal-arterji u l-vini.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom due to side effects, especially during the first eight weeks of therapy.
Maltese: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom tmien ġimgħat ta' kura.
English: Cometriq is available as capsules (20 and 80 mg).
Maltese: Cometriq jiġi bħala kapsuli (20 u 80 mg).
English: Cometriq has been given ‘conditional approval'.
Maltese: Cometriq ingħata ‘approvazzjoni kondizzjonali'.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Cometriq can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Maltese: Is-sommarju tal-opinjoni tal-Kumitat għall-Prodotti Mediċinali Orfni għal Cometriq jista' jinstab fuq issit web tal-Aġenzija: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Other information about Cometriq
Maltese: Informazzjoni oħra dwar Cometriq
English: This is a summary of the European public assessment report (EPAR) for Cometriq.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Cometriq.
English: The recommended dose is 140 mg once a day, taken as one 80-mg and three 20-mg capsules.
Maltese: Id-doża rakkomandata hija ta' 140 mg darba kuljum, meħuda bħala kapsula waħda ta' 80-mg u tlieta ta' 20-mg.
English: The active substance in Cometriq, cabozantinib, is a tyrosine kinase inhibitor.
Maltese: Is-sustanza attiva f'Cometriq, il-kabozantinib, hija inibitur tat-tirożina kinażi.
English: Cometriq is a cancer medicine that contains the active substance cabozantinib.
Maltese: Cometriq huwa mediċina kontra l-kanċer li fiha s-sustanza attiva l-kabozantinib.
English: The most common abnormal results in laboratory blood tests were increased liver enzymes such as aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP), low white cell counts (lymphopenia or neutropenia), thrombocytopenia (low blood-platelet counts), hypocalcaemia (low blood calcium levels), hypophosphataemia (low blood levels of phosphates), hypomagnesaemia (low blood magnesium levels), hypokalaemia (low blood potassium levels) and hyperbilirubinaemia (increased amounts of bilirubin, a breakdown product of red blood cells).
Maltese: Irriżultati anormali l-aktar komuni f'testijiet tad-demm fil-laboratorju kienu żieda fl-enzimi tal-fwied bħal aspartate aminotransferase (AST), alanine aminotransferase (ALT) u alkaline phosphatase (ALP), għadd baxx ta' ċelloli bojod (limfopenja jew newtropenja), tromboċitopenja (għadd baxx ta' plejtlits fid-demm), ipokalċemija (livelli baxxi ta' kalċju fid-demm), ipofosfatemija (livelli baxxi ta' fosfati fiddemm), ipomanjeżjemija (livelli baxxi ta' manjeżju fid-demm), ipokalemija (livelli baxxi ta' potassju fid-demm) u iperbilirubinemija (żieda fl-ammonti ta' bilirubin, prodott ta' tkissir taċ-ċelloli ħomor taddemm).
English: Why is Cometriq approved?
Maltese: Għaliex ġie approvat Cometriq?
English: Cometriq cabozantinib
Maltese: Sommarju tal-EPAR għall-pubbliku kabozantinib
English: The European Commission granted a marketing authorisation valid throughout the European Union for Cometriq on 21 March 2014.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Cometriq valida fl-Unjoni Ewropea kollha fil-21 ta' Marzu 2014.
English: The most common side effects with Cometriq (which may affect more than 2 in 10 people) are diarrhoea, palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome, which involves rash and numbness on the palms and soles), loss of weight, loss of appetite, nausea (feeling sick), tiredness, taste disturbances, changes in hair colour, hypertension (high blood pressure), inflammation of the mucosa (moist tissue that lines certain body cavities) including stomatitis (inflammation of the lining of the mouth), constipation, vomiting, weakness, and changes in the sound of the voice.
Maltese: L-effetti sekondarji l-aktar komuni b'Cometriq (li jistgħu jaffettwaw aktar minn 2 persuni minn kull 10) huma dijarea, is-sindrome ta' palmar-plantar erythrodysaesthesia (sindrome ta' id-sieq, li jinvolvi raxx u nuqqas ta' sensazzjoni fuq il-wiċċ tal-id u l-qiegħ tas-sieq), telf fil-piż, nuqqas ta' aptit, nawżja (tħossok ma tiflaħx), għeja, disturbi fit-togħma, tibdil fil-kulur tax-xahar, ipertensjoni (pressjoni taddemm għolja), infjammazzjoni tal-mukoża (tessut artab li jiksi ċerti kavitajiet tal-ġisem) inkluż stomatite (infjammazzjoni tar-rita tal-ħalq), stitikezza, rimettar, dgħjufija u tibdil fil-ħoss tal-vuċi.
English: What information is still awaited for Cometriq?
Maltese: Liema informazzjoni għadha mistennija għal Cometriq?
English: The most common serious side effects are pneumonia, inflammation of the mucosa, hypocalcaemia (low calcium levels in the blood), dysphagia (difficulty swallowing), dehydration, pulmonary embolism (blood clots in the vessels supplying the lungs), and hypertension.
Maltese: L-effetti sekondarji serji l-aktar komuni huma pulmonite, infjammazzjoni tal-mukoża, ipokalċemija (livelli baxxi ta' kalċju fid-demm), disfaġja (diffikultà biex tibla'), deidratazzjoni, emboliżmu pulmonari (tagħqid tad-demm fil-vażijiet li jissupplixxu lill-pulmuni), u ipertensjoni.
English: What are the risks associated with Cometriq?
Maltese: X'inhuma r-riskji assoċjati ma' Cometriq?
English: The side effects were considered manageable and were acceptable, compared with the limited other treatment options available.
Maltese: L-effetti sekondarji tqiesu maniġġabbli u kienu aċċettabbli, meta mqabbla mal-alternattivi limitati l-oħra ta' kura disponibbli.
English: The main measure of effectiveness was progression-free survival (how long the patients lived before their disease got worse): in patients given Cometriq this was 11.2 months, compared with 4.0 months in those given placebo.
Maltese: Il-kejl ewlieni tal-effikaċja kien issopravivenza mingħajr progressjoni (kemm damu jgħixu l-pazjenti qabel ma l-marda tagħhom marret għall-agħar): f'pazjenti li ngħataw Cometriq dan kien 11.2-il xahar, meta mqabbel mal-4.0 xhur ta' dawk li ngħataw il-plaċebo.
English: Cometriq had shown a benefit in patients with advanced medullary thyroid cancer unsuitable for surgery, who have few other treatment options.
Maltese: Cometriq wera benefiċċju f'pazjenti li kellhom kanċer tat-tirojde medullari avvanzat mhux xieraq għal kirurġija, li ftit għandhom alternattivi oħra.
English: Because the number of patients with medullary thyroid cancer is low, the disease is considered ‘rare', and Cometriq was designated an ‘orphan medicine' (a medicine used in rare diseases) on 6 February
Maltese: Peress li n-numru ta' pazjenti li jbatu minn kanċer tat-tirojde medullari huwa baxx, il-marda hija kkunsidrata ‘rari', u Cometriq ġie kklassifikat bħala ‘mediċina orfni' (mediċina li tintuża f'mard rari) fis6 ta' Frar 2009.
English: Since Cometriq has been granted a conditional approval, the company that markets Cometriq will provide information from a study comparing the safety and effectiveness of different doses of Cometriq, and its benefit in patients lacking the RET gene mutation or whose cancer has changes in another family of genes called RAS.
Maltese: Cometriq jista' jinkiseb biss b'riċetta ta' tabib u l-kura għandha tinbeda minn tabib li jkollu esperjenza fl-użu ta' mediċini kontra l-kanċer.
English: The full EPAR and risk management plan summary for Cometriq can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Għal aktar informazzjoni rigward il-kura b'Cometriq, aqra l-fuljett ta' tagħrif (parti wkoll mill-EPAR) jew ikkuntattja lit-tabib jew lill-ispiżjar tiegħek.
English: By blocking the activity of these receptors in cancer cells, the medicine reduces the growth and spread of the cancer.
Maltese: Billi timblokka l-attività ta' dawn irriċetturi fiċ-ċelloli tal-kanċer, il-mediċina tnaqqas it-tkabbir u t-tixrid tal-kanċer.
English: Teva Danmark A/S Østergade 38
Maltese: Teva Danimarka A/S Østergade 38
English: ROMÂNIA Str. Livezeni nr. 7A, Târgu Mureş,
Maltese: Livezeni nr. 7A, Târgu Mureş,
English: Plaza CEIN 5, Nave B-14Noain (Navarra) Spain
Maltese: Plaza CEIN 5, Nave B-14Noain (Navarra) Spanja
English: DK-1100 København K Denmark
Maltese: DK-1100 København K Danimarka
English: Str. Domniţa Ruxandra nr 12, parter, Sector 2, Bucureşti
Maltese: Domniţa Ruxandra nr 12, parter, Sector 2, Bucureşti
English: Rowex Ltd Bantry Co.Cork Ireland
Maltese: Rowex Ltd Bantry Co.Cork Irlanda
English: 2031 GA, Haarlem Netherlands
Maltese: 2031 GA, Haarlem Olanda
English: 2132 WT, Hoofddorp Netherlands
Maltese: 2132 WT, Hoofddorp Olanda
English: Veluwezoom 22 1327 AH, Almere Netherlands
Maltese: Veluwezoom 22 1327 AH, Almere Olanda
English: Belgium Teva pharma belgium Laarstraat 16
Maltese: Belġjum Teva pharma belgium Laarstraat 16
English: Eastbourne, East Sussex BN22 9AG United Kingdom
Maltese: Eastbourne, East Sussex BN22 9AG Renju Unit
English: Belgium Sandoz NV Telecom Gardens Medialaan 40
Maltese: Belġjum Sandoz NV Telecom Gardens Medialaan 40
English: Abbot Laboratories Ireland Ltd 4051 Kingswood Drive Citywest Business Campus Dublin 24
Maltese: Abbott Laboratories Ireland Ltd 4051 Kingswood Drive Citywest Business Campus Dublin 24
English: Medcor Pharmaceuticals B.V. Ketelmeerstraat 142-144 8226 JX, Lelystad Netherlands
Maltese: Medcor Pharmaceuticals B.V. Ketelmeerstraat 142-144 8226 JX, Lelystad Olanda
English: 1348 Ottignies/LLN Belgium
Maltese: 1348 Ottignies/LLN Belġjum
English: Wałbrzyska 13, 60-198 Poznan
Maltese: Biofarm Sp. z o.o. Wałbrzyska 13, 60-198 Poznan
English: Teva Sweden AB Järnvägsgatan 11 Box 1070
Maltese: Teva Svezja AB Järnvägsgatan 11 Box 1070
English: 1A Farma A/S Herstedøstervej 27-29 DK-2620 Albertslund Denmark
Maltese: 1A Farma A/S Herstedøstervej 27-29 DK-2620
English: ABBOT France 10, RUE D'ARCUEIL SILIC 233
Maltese: ABBOTT France 10, RUE D'ARCUEIL SILIC 233
English: 83602 Holzkirchen Germany
Maltese: 83602 Holzkirchen Ġermanja
English: SI - 1000 Ljubljana Slovenia
Maltese: SI - 1000 Ljubljana Slovenja
English: 04010 Campoverde di Aprilia Italy
Maltese: Campoverde di Aprilia Italja
English: Sibutramine-treated patients in SCOUT had a statistically significantly higher incidence of primary outcome events compared with placebo treatment (hazard ratio HR 1.161, p=0.016), driven by non-fatal MI (HR 1.275, p=0.022) and non-fatal stroke (HR 1.354, 0.026).
Maltese: Il-pazjenti trattati b'sibutramine fi SCOUT kellhom inċidenza statistikament sinifikanti ogħla ta' avvenimenti ta' eżiti primarji meta mqabbla mat-trattament bi plaċebo (proporzjon ta' periklu (hazard ratio) HR 1.161, p=0.016), ikkawżati minn MI mhux fatali (HR 1.275, p=0.022) u attakk mhux fatali (HR 1.354, 0.026).
English: Edvard Thomsens Vej 14 2300 København S Danmark
Maltese: Edvard Thomsens Vej 14 2300